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Abstract
The premature fusion of the paired frontal bones results in metopic craniosynostosis (MC) and gives rise to the clinical
phenotype of trigonocephaly. Deletions of chromosome 9p22.3 are well described as a cause of MC with variably penetrant
midface hypoplasia. In order to identify the gene responsible for the trigonocephaly component of the 9p22.3 syndrome, a
cohort of 109 patients were assessed by high-resolution arrays and MLPA for copy number variations (CNVs) involving 9p22.
Five CNVs involving FREM1, all of which were de novo variants, were identified by array-based analyses. The remaining 104
patients with MC were then subjected to targeted FREM1 gene re-sequencing, which identified 3 further mutant alleles, one
of which was de novo. Consistent with a pathogenic role, mouse Frem1 mRNA and protein expression was demonstrated in
the metopic suture as well as in the pericranium and dura mater. Micro-computed tomography based analyses of the
mouse posterior frontal (PF) suture, the human metopic suture equivalent, revealed advanced fusion in all mice
homozygous for either of two different Frem1 mutant alleles, while heterozygotes exhibited variably penetrant PF suture
anomalies. Gene dosage-related penetrance of midfacial hypoplasia was also evident in the Frem1 mutants. These data
suggest that CNVs and mutations involving FREM1 can be identified in a significant percentage of people with MC with or
without midface hypoplasia. Furthermore, we present Frem1 mutant mice as the first bona fide mouse model of human
metopic craniosynostosis and a new model for midfacial hypoplasia.
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Introduction
During development the calvarial bones are separated by regions
of non-calcified intrasutural mesenchyme which permit skull
deformation during birth and accommodate brain growth during
childhood. Craniofacial malformations caused by the premature
fusion of cranial sutures are common presenting features in clinical
genetics practice with an overall incidence of approximately 1 in
2500 live births. Non-syndromic forms of craniosynostosis predom-
inate, but there are more than 90 described syndromic craniosyn-
ostoses which are conventionally classified by their pattern of suture
involvement and dysmorphic features [1]. Syndromic craniosynos-
toses have been shown to arise from at least 6 different mechanisms;
activation of receptor kinase signaling pathways (FGFR1-3,
TGFBR1-2, EFNB1), inactivation of transcription factors (TWIST1,
MSX2), alterations to, or interactions with, extracellular matrix
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helicases (RECQL4) or membrane trafficking proteins (RAB23,
SEC23A) [2]. In contrast, the genetic etiologies of the non-
syndromic craniosynostoses are understood poorly. Metopic
craniosynostosis (MC) resulting in trigonocephaly occurs predom-
inantly as a non-syndromic craniosynostosis with an estimated
prevalence of between 1:15-68,000 live births [3,4]. A number of
reports suggest that MC has been under-diagnosed as the frequency
of identification is rising in multidisciplinary craniofacial units [3,5].
Review of the craniosynostosis literature, OMIM and the London
Dysmorphology database identifies more than 70 conditions that
can exhibit trigonocephaly/MC as a clinical feature (Table S1).
Syndromes with MC may be sub-classified into seven main
etiological groups including: common craniofacial syndromes
related to known craniofacial genes (FGFR family, TWIST); other
recognized clinical genetic syndromes resulting in microcephaly/
microencephaly; developmental disorders of the midline; recurrent
chromosomal/genomic copy number imbalances; syndromes with
abnormal metabolic function; teratogenic/environmental causes;
and an idiopathic group (Table S1).
One of the better characterized forms of MC is associated with
monosomy for an 8Mb interval of chromosome 9p22.3 (OMIM
158170). The major clinical features of this contiguous gene
deletion syndrome are mental retardation, trigonocephaly,
midface hypoplasia and a long philtrum [6–10]. Swinkels et al.,
mapped the trigonocephaly component by array-CGH to a
genomic interval of 300 kb [11]. This region partially overlaps the
interstitial deletion identified by Kawara et al., in a patient with
trigonocephaly who had a complex cytogenetic re-arrangement
[12]. Jehee et al., sequenced CER1, a candidate gene located
within that interval, but failed to identify any pathogenic changes
in a cohort of 70 syndromic and non-syndromic trigonocephaly
patients [13]. It is noteworthy that CER1 is located immediately
telomeric to the interval described by Swinkels et al., and that
another interesting candidate gene, FREM1, is in close proximity
to the breakpoints defined previously [11].
The role of intrasutural mesenchyme extracellular matrix
(ECM) components in determining normal sutural development
is underscored by the frequent cranial suture involvement in
Marfan syndrome and the demonstration that proteoglycan/FGF9
interactions regulate sutural growth factor concentrations [14].
Because of this, we became interested in FREM1, which resides in
the 300 kb interval defined by Swinkels et al [11] as a candidate
for metopic craniosynostosis. FREM1 is a secreted protein of
mesenchymal cells which forms a ternary complex with the
epithelial cell integral membrane proteins, FRAS1 and FREM2,
mutations in which have been found in patients with Fraser
syndrome (OMIM 219000) whose clinical phenotype includes
craniofacial dysmorphism. FREM1 is expressed in regions of
epidermal/mesenchymal interaction and remodelling and shows
notable embryonic expression in midline structures [15]. Homo-
zygous recessive mutations in FREM1 have been identified
recently in two rare conditions: BNAR syndrome which is
characterized by bifid nose, anorectal malformations and renal
agenesis (OMIM 608980) [15] and; Manitoba-Oculo-Tricho-Anal
(MOTA) syndrome (OMIM 248450), which is characterized by a
bifid or broad nasal tip, eye colobomas, cryptophthalmos and
anophthalmia/microphthalmia, aberrant hairline and anal steno-
sis [16].
In this report we provide evidence that mutations in FREM1
can also be associated with trigonocephaly. We have identified 8
mutant alleles of human FREM1 in a variety of mutational classes
including structural variants that interrupt the FREM1 gene,
CNVs of the entire FREM1 locus and point mutations of the
FREM1 coding sequence. These results are supported by Frem1
gene expression studies, suture imaging and quantitative analysis
of craniofacial shape in heterozygous and homozygous Frem1
mutant mice.
Results
The initial stage of our analysis was to re-examine the CNV
described in the three patients defining the 300 kb trigonocephaly
interval reported by Swinkels et al., using high density chromo-
some 9 specific arrays (patients 1-3; [11]). These results re-defined
the CNV boundaries in these patients compared with the results
obtained with lower resolution BAC arrays. Furthermore, an
additional patient with MC had been ascertained subsequent to
the report of Swinkels et al., who was found to have an interstitial
CNV of distal 9p (patient 4). Genomic analyses in these four
subjects re-defined the region contributing to MC in the 9p
deletion syndrome.
CNVs in patients with MC disrupt the FREM1 gene
The CNVs identified in each of these four patients are
summarised in Figure 1a, Table 1 and are as follows. Re-analysis
of two previously reported CNVs identified that they contained
deletion breakpoints within the FREM1 gene. Patient 1 was shown
to have a 14.83 Mb deletion which extended from FREM1 intron
9 to the chromosome 9p telomere, deleting exons 10-37 of
FREM1. Patient 2 had a complex chromosome 9 deletion-
duplication mutation with a breakpoint within FREM1. The
deletion component of this re-arrangement extended from FREM1
intron 6 to the 9p telomere, deleting exons 7-37 of FREM1. The
FREM1 sequence immediately centromeric to the deletion formed
a 37 Mb duplication extending between genomic co-ordinates
14.84 Mb and 51.8 Mb [hg18].
The third CNV was a 15.32 Mb deletion in Patient 3 which
extended from the chromosome 9p telomere to the intergenic
region between TTC39B and SNAPC3 resulting in the deletion of
the entire FREM1 locus. Patient 4 had the smallest CNV; a
2.14 Mb interstitial 9p deletion between genomic co-ordinates
Author Summary
Although twin and family studies have shown that genes
play a critical role in the timing of fusion of skull bones, the
identification of specific genes that may be involved has
remained somewhat elusive except in the case of the
dominantly inherited craniosynostosis syndromes. Metopic
craniosynostosis (MC), the early fusion of the forehead
(frontal) bones, accounts for 5%–15% of all craniosynos-
tosis cases. This premature fusion of the frontal bones
results in a characteristically altered skull shape, termed
trigonocephaly, that usually requires surgical correction.
Remarkably, the cause of the majority of cases of MC
remains unknown (idiopathic). Here, we report genetic
variants involving chromosome 9 which involve and
interrupt the structure of the FREM1 gene in a large
cohort of patients presenting with unisutural metopic
craniosynostosis. Micro-computed tomographic (microCT)
imaging and quantitative analysis of skull shape reveal
both premature fusion of the PF suture (metopic
equivalent) and also changes in frontal bone shape
supportive of a role for Frem1 in regulation of the metopic
suture. Taken together with Frem1 gene and protein
expression findings, these data indicate that mutations in
FREM1 can give rise to metopic craniosynostosis.
FREM1 Mutations in Metopic Craniosynostosis
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region extends from NFIB intron 2 to the intergenic region
between C9orf93 and BNC2 also deleting FREM1. All CNVs were
confirmed by MLPA and were shown to be de novo.
The common 0.65 Mb region of deletion overlap identified in
the four samples contains 4 genes NFIB, ZDHHC21, CER1 and
FREM1. Importantly two patients were identified to have CNVs
whose boundaries disrupt the coding region of the FREM1 gene.
These CNV data are consistent with a model in which
haploinsufficiency of FREM1 is associated with MC. These
findings prompted us to investigate whether DNA sequence
analysis of FREM1 might identify additional pathogenic muta-
tions.
Prior to re-sequencing of the 35 coding exons of FREM1 (see
below), the 105 additional patients with MC were pre-screened for
point mutations in CER1 and deletions of FREM1. One further
patient (patient 5) was confirmed to have a whole FREM1 gene
deletion as a result of a cytogenetically visible 9p22.3 deletion. No
mutations were identified in CER1, consistent with previous
reports [13].
Missense mutations in FREM1 in patients with MC
104 patients with a clinical diagnosis of MC were screened for
DNA sequence mutations in FREM1. Two previously unreported
nucleotide substitutions were identified in three patients (Table 1;
Figure 1c). The first of these mutations, NM_144966.4:c.
4499A.T [NP_659403.4: p.(Glu1500Val)] in exon 25, was
observed in two unrelated patients (patient 6 and patient 7).
p.Glu1500Val was also present in patient 6 as a de novo event
(Figure 1b) consistent with both his parents being clinically
normal. The Grantham score for this substitution is substantial at
121 and the mutation is predicted not to be tolerated by SIFT, and
possibly damaging by Polyphen2 [HumVar] with a score of 0.309
[17–19]. The PhyloP score for nucleotide conservation for
chr9:g.14766145 is 2.55 suggesting it is under negative selection
[20]. This mutation was not detected in 142 control chromosomes
of Caucasian origin and 110 ethnically matched control
chromosomes consistent with it not being a population polymor-
phism. The second instance of the p.Glu1500Val mutation was
identified in patient 7 and his mother, who had craniofacial
features which included hypertelorism and up-slanting palpebral
fissures. Both of the proband’s female siblings had also inherited
the mutation; one sister had ptosis and hypertelorism (Table S2).
The second individual had no abnormal craniofacial findings.
The second mutation, NM_144966.4:c.1493G.A [NP_659
403.4:p.(Arg498Gln)], in exon 9, was observed in a single patient
(Patient 8). Although the Grantham score is only 43, this amino
acid is highly conserved with 20 vertebrate species having an
Figure 1. Schematic overview of CNVs and mutations affecting the FREM1 gene. (a) Deletions in patients 1-4 are represented by solid red
bars, whereas the duplicated segment in patient 2 is represented by a solid green bar. The proximal deletion breakpoint of patient 1 as well as the
deletion/duplication breakpoint in patient 2 disrupts FREM1. (b) Partial electropherograms of the de novo mutated nucleotide identified in patient 6.
(c) Schematic overview of the FREM1 protein showing the domain structure and positions of mutations in the FREM1-trigonocephaly (above) and
BNAR (below) syndromes.
doi:10.1371/journal.pgen.1002278.g001
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conservation for chr9:g.14832559 is 2.79. It is predicted as not
being tolerated by SIFT, and probably damaging by Polyphen2
[HumVar] with a score of 0.996. The proband was born to a 35
year old G1 P0 mother and 32 year old father at full term by
Caesarian section. He had isolated MC corrected at six months of
age. There was no family history of craniofacial dysmorphism. A
fetal ultrasound at 20 weeks was reported as normal. The birth
weight was 3.42 kg (75-90
th centile), length 50.8 cm (50-75
th
centile). Craniosynostosis was suspected at birth and confirmed by
a cranial CT scan at five months of age. The proband is currently
four years of age with normal development. The mutation was
proven to be paternally inherited but was absent in 138 control
Caucasian chromosomes excluding a population polymorphism.
A third potential FREM1 mutation NM_144966.4:c.854A.G
[NP_659403.4:p.(Tyr285Cys)], in exon 6, was identified in a
proband in a Brazilian family however this mutation did not
segregate with the disease and was detected in 1 of 142 control
chromosomes of Caucasian origin and 5 of 120 ethnically matched
control chromosomes. These results are consistent with this variant
being a novel population polymorphism.
Frem1 is expressed in the developing frontal and nasal
sutures in mice
To ascertain a potential role for Frem1 in the formation of the
metopic suture we examined the expression of the gene prior to
fusion of the suture in wildtype mice. In situ hybridization of mouse
embryos from mid to late gestation (E14.5–E16.5) delineated
expression of Frem1 between the developing frontal bones in the
region fated to form the posterior-frontal suture (Figure 2).
Antibody staining at P0 highlighted fibrillar pericranial expression
of Frem1 overlying the developing frontal bones as well as staining
in the dura mater underlying these bones. Low levels of diffuse
Frem1 staining were also noted in the osteogenic precursors
between the frontal bones, further suggesting a role for the protein
in the development of the posterior frontal suture.
Table 1. Molecular and clinical patient information.
Patients with CNVs affecting FREM1 Patients with mutations affecting FREM1
Patient
1*
Patient
2*
Patient
3*
Patient
4*
Patient
5
Patient
6
Patient
7
Patient
8
FREM1 mutation Del ex10-37 Dup ex1-6;
Del ex7-37
Del Del Del c.4499A.T;
p.Glu1500Val
c.4499A.T;
p.Glu1500Val
c.1493G.A;
p.Arg498Gln
Inheritance de novo de novo de novo de novo de novo de novo maternally
inherited
paternally
inherited
General Clinical features
developmental delay + + ++++ 22
speech delay + + +++NA 22
motor delay + unknown + 22NA 2 6
hypotonia ++222NA 2 6
height -1 SD -2 SD -1.5SD -1.5 SD -1SD NA -1SD 2
Head
trigonocephaly + + ++++ + +
midface hypoplasia + 6 +++NA 6 2
eyes upward slant 2 ++ 2 + NA 2
downward slant 2 2 222NA + 2
short palpebral fissure ++6 2 unknown NA 22
epicanthic folds 2 + 2 + 2 NA 6 2
high arched eyebrows 22+ 2 + NA 22
head circumference unknown unknown 0 SD 0 SD unknown NA -3SD 2
nose short/flat short/flat short/flat short short NA Broad
bridge
Flat nasal
bridge
Additional clinical features
renal abnormalities 2 2 222NA Mild Right
Pelvicaliceal
dilatation
2
abnormal genitalia 22cryptorchidism22NA 22
inguinal hernia 22++2 NA 22
cardiac malformations 22PS/I PPS VSD + 22
other 2 2 2222 Hypoglycemic
neonatal seizures
2
*More detailed clinical descriptions can be found in Swinkels et al. (ref11); del, deletion; dup, duplication; ex, exon; SD, standard deviation; PS/I. Pulmonary stenosis/
incompetence; PPS, peripheral pulmonary stenosis; VSD. Ventriculo-septal defect ; +, present; 2, absent ; NA, not available.
doi:10.1371/journal.pgen.1002278.t001
FREM1 Mutations in Metopic Craniosynostosis
PLoS Genetics | www.plosgenetics.org 4 September 2011 | Volume 7 | Issue 9 | e1002278Frem1 mice show craniofacial abnormalities consistent
with MC
Semi-landmark-based geometric morphometrics is a powerful
means of distinguishing localized differences in form between two
groups. We therefore used this approach to obtain further
evidence as to whether Frem1 mutations can cause MC. The
skulls of bat mutant mice were imaged by mCT and analyzed using
semi-landmark-based geometric morphometrics over the antero-
frontal aspects of the skull (coronal suture to nasal tip). Results of
principal components analysis of the posterio-frontal aspects of the
cranium revealed that the first two principal components (PC1 and
2) account for more than 45% of the variation in the dataset (data
not shown). PC1 is usually correlated with the size of the
individuals. In geometric morphometrics, size of the specimen is
determined by the centroid size, which is the square root of the
summed distances between the centroid (arithmetic mean of
landmarks) and each landmark of the specimen. Regression of the
first two PCs against centroid size showed that size was not
correlated with either of the principal components (F testpc1: 1.8
on 1 and 18 DF, p-value: 0.1964; F-testpc2: 0.9419 on 1 and 18
DF, p-value: 0.3447). In contrast, regression of the first two PCs
against the groups (homozygotes, heterozygotes, and wildtype)
showed a significant correlation with the genotype of the
individuals (for PC1: R
2=0.3943 F-statistic: 5.533 on 2 and 17
DF, p-value: 0.0141; for PC2: R
2=0.3604, F-statistic: 4.789 on 2
and 17 DF, p-value: 0.02241) (Figure 3b).
Overlay of the mean positions of each semi-landmark between
homozygotes and wildtype skulls showed that the homozygote
upper midfaces were raised along the proximal aspect of the
metopic suture (black arrowheads, Figure 3c) and were signifi-
cantly wider at the level of the coronal suture (compare colored
arrows, Figure 3c). Notably, the increased width in the
homozygotes is more prominent posteriorly. Furthermore, the
lateral aspects of the homozygote skulls decline more sharply than
controls (colored arrows Figure 3c and white arrowheads in
Figure 3d). Heterozygotes also show a decline at the lateral aspects
although this was less pronounced than in homozygotes.
Also of significance, one of the homozygotes from this initial set of
imaged skulls showed marked deviation of the midface. To
investigate this further, we scanned an additional 25 male heads
from mutant and wildtype mice ranging in age from 28 days to 240
days, including 13 homozygotes and 7 heterozygotes. Visual
inspection of 3D rendered images of each skull revealed varying
degrees of midfacial asymmetry and/or midface hypoplasia in a
significant proportion of Frem1 homozygotes(7/16 total;45%- when
also including those used in the shape analyses; Figure 4) and to a
lesser degree the Frem1 heterozygotes (2/21 total; 9.5%). For the
homozygotes, leftward deviation was more frequent than rightward
deviation (5 left vs 1 right; 1 general hypoplasia). In summary,
morphometric analysis of skulls from bat homozygous and hetero-
zygous mice identified craniofacial malformations consistent with the
craniofacial features, in particular MC and midfacial asymmetry/
hypoplasia, seen in the 9p22 deletion syndrome, with the penetrance
of the phenotypes in mice correlated to mutant gene dosage.
Different Frem1 mutant alleles show advanced fusion of
the posterior frontal suture in mice
To investigate the basis for the altered frontal cranial shape,
three-dimensional rendered images generated from scans of Frem1
bat
homozygote, heterozygote and wildtype skulls were sectioned
virtually in the coronal plane at the equivalent position on the
posterior frontal suture. Examination of the suture in control
C57BL/6J mice revealed a generally patent suture with only
intermittent contact between the frontal bones either endocranially
or ectocranially. In contrast, age, sex and background matched
Frem1 homozygote animals all exhibited complete fusion of the PF
suture (Figure 5). Notably, 42% of heterozygous animals showed
variable sutural anomalies including complete fusion (1/14; 7%),
obvious sutural asymmetry (3/14; 21%) and advanced endocranial
suture fusion (2/14; 14%). Importantly, the findings in the Frem1
bat
Figure 2. Frem1 expression in the developing frontal and nasal sutures in mice. (a,b) Frem1 transcripts are detected in the developing
cranial sutures and in the regions fated to form the posterior-frontal suture, the metopic suture equivalent that is affected in cases of metopic
craniosynostosis (white arrowheads) (c) Immunostaining for Frem1 (red) of the frontal bones at postnatal day 0 reveals expression of the protein in
the pericranium and dura mater on either side of the frontal bones (dotted line; fb = frontal bone, hf = hair follicle). Samples have been
counterstained with DAPI (blue) and with an antibody to entactin (green) which marks the basement membrane of the epidermis and hair follicles.
The boxed area (yellow) is magnified in (d) highlighting fibrillar staining for Frem1 above and below the frontal bone (fb) (e) Frem1 protein was also
noted diffusely in the suture mesenchyme at the medial edge of the frontal bones, with d’ and e’) showing the identical images in black and white to
emphasize the fibrillar localization of Frem1. Scale bars = 50 mm.
doi:10.1371/journal.pgen.1002278.g002
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second Frem1 mutation, the Frem1
Qbrick null allele; the single
homozygote mouse showed complete fusion of the PF suture, while
two of the three heterozygotes analyzed showed similar suture
anomalies to those seen in Frem1
bat heterozygotes (Figure 5).
To investigate whether either of the two remaining genes within
the refined critical interval might also contribute to the
craniofacial phenotype of the 9p22 deletion syndrome, we first
analyzed a small number of Zdhhc21
dep/dep homozygotes. Compar-
ison of these mice to the analyzed Frem1 mice (37d vs 28-30d),
demonstrated that none had PF suture fusion or sutural anomalies
(data not shown). Assessment of the cranioskeletal phenotype of
late stage homozygous Nfib
-/- fetuses with age matched C57BL/6J
control embryos showed that the Nfib
-/- fetuses exhibited reduced
overall size and relatively delayed cranial bone growth (data not
shown), but without evidence of premature suture fusion.
Discussion
In this study we report that FREM1 is a dominantly-acting
metopic craniosynostosis gene based upon findings of: i) patients
with trigonocephaly with CNVs which disrupt or delete the coding
sequence of the gene; ii) missense mutations in FREM1 in patients
with isolated MC; iii) expression of mouse Frem1 gene and protein
in the posterior frontal suture (metopic suture equivalent); iv)
advanced fusion of the PF suture, altered frontal bone curvature
and midfacial malformations in two independent mouse lines
carrying distinct Frem1 loss-of-function mutations, and: v) absence
of an overt cranial suture phenotype in mice deficient in either of
the two remaining genes (Zdhhc21 and Nfib) that reside within the
9p22 critical interval.
FREM1 is composed of several functional domains, including a
conserved signal sequence, a CALXb calcium-binding loop
typically found in Na
+-Ca
+ exchange proteins, 12 chondroitin
sulfate proteoglycan (CSPG) elements, and a C-terminal lectin
Type C domain [21]. FREM1 is a basement membrane protein
which forms a ternary complex with the FRAS1 and FREM2
proteins, although the topology and stoichiometry of the subunits
is not certain. FREM1 orthologs are highly conserved throughout
evolution and the 12 CSPG repeats are highly homologous with
each other. Both point mutations observed in the MC cohort affect
residues within the CSPG repeats whose physico-chemical
Figure 3. Frem1 mCT and morphometric analysis in mice are consistent with the human MC phenotype. mCT and morphometric
analysis of mouse skulls at postnatal day 28 reveal anterofrontal cranial deformation (a) semi-landmark mesh over nasal and frontal bones of control
skull; (b) plot of principal component 1 (PC1) and PC2 reveal that heterozygote (green dots) and homozygote (red dots) bat mice each have distinct
craniofacial shapes from age, sex and genetic background matched controls (blue dots); (c) average mesh coordinates of control (blue dots) versus
Frem1 homozygotes (red dots) show changes in shape over the frontal bones. These differences can also be seen in (d) by comparison of identical
cross-sections. These deformations are reminiscent of the trigonocephalic changes seen in patients with FREM1 mutations.
doi:10.1371/journal.pgen.1002278.g003
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Prediction of the consequences of these mutations, based on
similarity to the structurally related NG2 protein, suggest they
affect surface residues of FREM1, potentially disturbing the
interactions with other proteins. CSPG repeats of the NG2
proteoglycan have been shown to interact with basic fibroblast
growth factor [22]. It is intriguing to speculate that FREM1 could
also bind FGFs and that the craniosynostosis associated with a
mutation in these repeats arises through altered FGFR activation
as a result of increased intrasutural FGF availability or its affinity
for their receptors. A similar mechanism has recently been shown
for the Eks mouse which carries a gain-of-function mutation in
Fgf9 [14].
Recently, Alazami et al. (2009) demonstrated expression of
Frem1 in the developing midface by whole mount in situ
hybridization in normal embryonic day 11.5 mice, consistent with
the midfacial phenotypes seen in both BNAR and FREM1-
trigonocephaly [15]. We have now demonstrated that expression
of Frem1 mRNA is also present in the developing interfrontal
suture. These findings are also validated by immunohistochemical
detection of Frem1 protein within the sutural mesenchyme as well
as in the dura mater and pericranium prior to the initiation of the
posterior frontal suture at postnatal day 7. We speculate that
expression of FREM1 within the intrasutural mesenchyme would
be consistent with a role in modulating Fgf or other growth factor
availability.
An important role for Frem1 in regulating suture patency is
supported by our mCT investigations of Frem1
bat and Frem1
Qbrick
mice. Previous studies have established that the posterior frontal
suture in C57BL/6J mice begins to fuse after postnatal day 25 and
morphologically completes fusion around day 45. This timing is
consistent with the findings in our postnatal day 28-30 wildtype
Figure 4. Variable presentation of midface hypoplasia/assymetry in Frem1 mutant mice. Multiple views from rendered mCT
reconstructions of P28 wildtype (far left column) and homozygote male Frem1 mice. Around 45% of homozygotes exhibited some readily apparent
dysmorphology involving the midfacial region. Four examples of homozygote skull morphology observed: (i) pronounced leftward deviation of
midface, (ii) uniform midface hypoplasia (shortened snout), (iii) leftward deviation extending from posterior frontal suture through to nasal tip, (iv)
pronounced rightward deviation of midface. Frontal views of the homozygote skulls reveal medial depression along the internasal suture and/or
marked curvature of the nasal bones (see white arrow in column (ii). Most homozygotes display abnormal maxillary-premaxillary suture morphology
(compare asterisks in lateral and ventral views of control and homozygote (i).
doi:10.1371/journal.pgen.1002278.g004
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In contrast, virtual cross-sectional analysis of Frem1
bat and
Frem1
Qbrick homozygotes revealed almost complete fusion of the
posterior frontal suture, both ectocranially and endocranially
(Figure 5). Importantly, heterozygotes of each mutation also
showed variable posterior frontal sutural anomalies ranging from
complete fusion to atypical sutural asymmetry to a normal
appearing suture. Furthermore geometric morphometric analysis
of heterozygote and homozygote Frem1
bat skulls and wildtype
genetic background controls revealed that Frem1 mutant mice
show altered frontal bone curvature, in particular at the level of
the posterior frontal suture. Although more evident in the
homozygote skulls, the medial aspects over the posterior frontal
suture appear raised relative to the lateral aspects which decline
more sharply than in controls (see Figure 3a and 3b). The variably
penetrant posterior frontal suture anomalies in Frem1 heterozy-
gotes and the lack of overt cranial and/or sutural defects in
homozygous Zdhhc21 and Nfib mutants supports a causative role
for FREM1 haploinsufficiency in the 9p22.3-trigonocephaly in
humans. Further to this, the analyses of the mouse craniofacial
skeleton also revealed that homozygous Frem1
bat mice, and to a
lesser extent heterozygote mice, generally have a shorter upper
midface, including nasal bone and premaxilla (midfacial hypopla-
sia/asymmetry) and slightly wider nasal bones (Figure 4). These
findings are consistent with the earlier reported expression of
Frem1 in the developing facial prominences and the role of
recessive FREM1 mutations in BNAR syndrome [15]. Notably,
midface hypoplasia is one of the major clinical features of 9p22.3-
trigonocephaly and was noted in at least six of the eight probands
reported here (Table 1).
The FREM1 mutational classes identified in humans include
structural variants that interrupt the gene, CNVs of the entire
FREM1 locus and point mutations of the FREM1 coding sequence.
The observed mutational heterogeneity is reminiscent of other
dominantly-acting mutations of ECM multimeric proteins such as
collagen type 1 a1, collagen type 1 a2 [23] and fibrillin [24] where
multi-exon deletions and missense mutations both result in the
same disease phenotype. It is interesting to note however, that the
FREM1 mutations identified in this study are heterozygous
(dominantly acting) with the morphological consequences largely
restricted to the craniofacial complex (metopic suture and midface)
compared with the multi-organ involvement in the autosomal
recessive disorder, BNAR. The phenomenon of dominant and
recessive mutations in the same gene is well described and
associated with a range of molecular etiologies. Classically,
recessive mutations may produce a spectrum of disorder severity
based on allele dosage, as has been described in familial
hypercholesterolemia [25]. Alternatively autosomal dominant gain
of function mutations may be associated with a different spectrum
of disease compared with loss of function mutations. This is
exemplified by heterozygous gain of function mutations in RET
which are associated with thyroid carcinoma and multiple
endocrine neoplasia types 2A and 2B versus homozygous loss of
function mutations in Hirschsprung disease [26]. Finally, domi-
nant and recessive mutations may involve different stages of
protein biosynthesis or functional domains, as described for
mutations in the insulin gene in which dominant neonatal diabetes
arises from mutations associated with misfolding of proinsulin
whereas recessive mutations reduce insulin biosynthesis [27]. The
difference in range and severity of organ involvement is consistent
with MC arising as a result of haploinsufficiency for FREM1.
BNAR and FREM1-trigonocephaly could therefore be considered
to form a spectrum of disorders within the same genetic pathway
distinguished by dominant and recessive inheritance.
Phenotypic variability and incomplete penetrance are typical
findings in the TWIST1 and FGFR-associated craniosynostoses
and are therefore not unexpected findings in this MC patient
cohort. The p.Glu1500Val mutation was present in de novo form in
one affected individual. In a second family this mutation was
inherited from the proband’s mother who has facial features of
hypertelorism (.3SD) and upslanting palpebral fissures. The
mutation was also present in three siblings, one of whom (the
proband) had trigonocephaly and microcephaly (,3SD), a sister
who had ptosis and hypertelorism, and a third sibling who has
relative hypertelorism but no significant findings. Similarly, the
p.Arg498Gln mutation was inherited from a clinically unaffected
father.
In line with the variable clinical presentations, Frem1
bat mice
have been previously reported as showing a number of variably
penetrant features including renal agenesis (,20%), limb (digit)
anomalies (,5%) and unilateral or bilateral crytophthalmos [21].
However, mouse lines carrying other mutant Frem1 alleles (that
arose on different inbred backgrounds) typically do not present
with renal phenotypes and show variable penetrance of other
features as well [28,29]. The variable expression and penetrance of
skull deformations in the inbred Frem1
bat line is consistent with
Figure 5. Frem1
bat and Frem1
Qbrick mice exhibit advanced posterior frontal suture fusion. Rendered 3D images of postnatal day 28 heads
were generated from microcomputed tomographic scan data and each virtually sectioned in the coronal plane at the same position through the
posterior frontal suture (i – dorsal view of position of coronal plane; ii – frontal view of rendered image in (i)). The region indicated by the rectanglei s
shown in (iii) for a control (+/+) skull, homozygote Frem1
bat (bat/bat) and Frem1
Qbrick (qb/qb) skulls, as well as different heterozygote Frem1
bat (bat/+)
and Frem1
Qbrick (qb/qb) skulls. The most severely affected heterozygote Frem1
bat (bat/+) posterior frontal suture is also shown. Control skulls all
showed sparse points of contact (typically just on the endocranial surface) between the frontal bones, indicative of the early stages of suture fusion.
Fusion of the posterior frontal suture is largely completed by ,postnatal day 45 in controls. In contrast, the Frem1
bat/bat and Frem1
qb/qb skulls
exhibited extensive fusion both on the endocranial and ectocranial surfaces (arrowheads) at day 28, indicating advanced fusion of this suture.
Heterozygotes also showed variable suture anomalies, from complete fusion to asymmetry of the suture.
doi:10.1371/journal.pgen.1002278.g005
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presentation of the Frem1 mutant phenotype and that of the
broader family of blebs mouse mutants which carry mutations in
the other Fras/Frem genes has been confirmed by placing the
same mutations on different backgrounds (I. Smyth, personal
communication). We therefore speculate that the variable
penetrance and expressivity of the human FREM1 mutations is
due to a combination of factors, including genetic modifiers and
epigenetic modulators. Such penetrance and expressivity must
therefore be considered when counseling patients in regard to
recurrence risk. This group of clinical findings suggest that the
phenotypic consequences of FREM1 mutations in humans and
mice include but are not limited to MC.
In summary, we provide evidence that FREM1 mutations are
associated with trigonocephaly. Taken together, our data support
a role for FREM1 in the closure of the metopic as well as
premaxillary-maxillary sutures and suggest further avenues for
study into unisutural synostosis biology. Furthermore, we present
the Frem1 mouse as a new animal model for both trigonocephaly
and facial asymmetry.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the
University of Washington Research Ethics Committee.
Patients
109 patients with non-syndromic MC were ascertained from
five participating centers of the International Craniosynostosis
Consortium (http://genetics.ucdavis.edu/icc.cfm) (University of
California, Davis, USA n=34; Seattle Children’s Hospital,
Seattle, USA, n=33; Universidade de Sa ˜o Paulo, Sa ˜o Paulo,
Brazil, n=24; Australian Craniofacial Unit, Adelaide, Australia,
n=14; and RUNMC, Nijmegen, The Netherlands n=4). DNA
was isolated or purified using a QIAamp DNA mini kit (QIAgen,
the Netherlands) following standard procedures. Parental samples
were collected when available, and informed consent was obtained
in all cases following local institutional human research ethics
guidelines. Mutation pre-screening of the regions of the FGFR and
TWIST1 genes associated with syndromic craniosynostosis was
performed by bi-directional DNA sequence analysis; including
FGFR1 exon 7, FGFR2 exons 3, 5, 8, 10, 11 and 14-17, FGFR3
exons 7 and 10 and TWIST1 [30,31].
Fine mapping of CNVs using chromosome 9 microarray
analyses
Chromosome 9 specific oligonucleotide microarray analyses
were performed using a 385K array following the manufacturer’s
instructions (Roche NimbleGen). The acquired images were
analyzed using NimbleScan V2.4 extraction software (Roche
NimbleGen). Data were visualized in SignalMap V1.9 software to
determine the boundaries of the CNVs (Roche NimbleGen).
Multiplex ligation-dependent probe amplification (MLPA)
of FREM1
An in-house MLPA kit was developed to screen for CNVs at
9p22.3. A set of uniquely-sized MLPA probes hybridizing to exon
2o fCER1, exons 2, 9, 16, 23, 31 of FREM1 and to intron 8 of
TTC39B were developed. These MLPA probes were combined
with four unlinked standard control probes. All probes were
designed following the protocol of MRC-Holland and the
sequences are provided in Table S3 (http://www.mlpa.com/
index.htm). Hybridization, ligation and amplification of the
MLPA probes were performed as described previously [32].
Amplification products were identified and quantified by capillary
electrophoresis on an ABI3730 or 3100 Genetic Analyzer, using
GeneMapper software (Applied Biosystems).
Sequence analysis of CER1 and FREM1
All coding regions and adjacent splice sites of CER1
(NM_005454) and FREM1 (NM_144966) were amplified and
sequenced (PCR primers and conditions available on request).
PCR products were cycle sequenced (ABI 3730 or 3100) and
analyzed for mutations using the Vector NTI v11 software
together with visual inspection. Potential mutations were tested for
de novo occurrence through mutation analysis of parental DNA
where available. Sequence variants are described following the
HGVS nomenclature guidelines.
Mouse strains
Mice carrying the ENU-generated Frem1
bat mutation main-
tained on a C57Bl/6J background were used for this study. The
bat allele is the result of a single nucleotide change that affects the
normal mRNA splicing of exon 25 of the mouse Frem1 gene,
leading to a frameshift and premature truncation of the protein.
The mutant allele is thought to be hypomorphic rather than a null
allele [21]. Standard mating protocols were used to generate
heterozygote and homozygote animals that were each identified by
PCR-based genotyping [21]. Mice were sexed based on genital
morphology at weaning. A single litter of mice carrying a Frem1
null allele (Frem1
Qbrick) was also made available for analysis,
including three heterozygous animals, one surviving homozygote
and three littermate C57BL/6J controls. These mice were
generated by a traditional gene targeting approach [28] and also
maintained on a pure C57BL/6J background. A small number of
mice from mutant lines representing both of the remaining genes
that reside within the refined critical interval, ZDHHC21 and
NFIB, were also obtained. The Zdhhc21
dep line [33] carries a three
base pair deletion (single amino acid deletion) that results in
protein mislocalization and loss of enzyme activity and is
associated with delayed hair shaft differentiation. The remaining
mutant carries a null allele of Nfib, generated through traditional
gene targeting [34]. Nfib heterozygotes are apparently healthy and
show no overt phenotype, while Nfib homozygotes die just prior to
birth. A limited number of late stage homozygous Nfib
-/- fetuses
were available. Both lines were provided on a C57BL/6
background.
Micro-computed tomography (mCT) and skull shape
analysis
For the purpose of assessing suture patency and comparing
cranial shape, a total of 21 specimens were subjected to mCT
using a Skyscan model 1076 in-vivo microtomograph (Skyscan,
Belgium). All specimens were scanned at the Small Animal
Tomographic Analysis (SANTA) Facility at the University of
Washington, using and following optimized protocols (0.018 mm
voxel resolution, 65 kV, 150 uA, 1.0 mm Al filter) previously
reported [35,36]. Out of the 21 specimens, three were homozy-
gotes, four were wild-type and the remainder were Frem1
bat
heterozygotes. A further seven 4 week-old Frem1
Qbrick mice (three
heterozygotes, one homozygote, and three C57Bl/6J controls)
were also scanned. Raw scan data were reconstructed using
NRecon software (Skyscan, Belgium) and rendered using the
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au/Vizlab/drishti/). Virtual cuts in the coronal plane were then
made at the same planar level in each rendered skull to assess the
patency of the posterior frontal suture. To ensure direct
comparability, all scan, reconstruction and rendering parameters
were kept identical for all skulls.
3D mesh models of each skull created using the CTan software
(Skyscan, Belgium) and were then imported into Rapidform (Inus
Technology) in which the mandibles and other unwanted elements
were segmented out. Cleaned meshes were then imported into the
3D landmark software developed by the Institute for Data Analysis
and Visualization (IDAV Landmark). A flexible patch was applied
to the region between the rostrum and the coronal suture in the
dorsal view. Each patch had 9 control points anchored to
biologically homologous structures to ensure the consistency of
the patch placement (Figure 3a inset). Finally, the patch was
converted into a 15621 deformable grid, and the 3D coordinates
of 315 grid points were exported. Due to some mesh inconsisten-
cies, the Landmark software could place 309 of 315 grid point in
all skulls, and these were used in all subsequent analyses. 3D
renderings of the skulls indicated a high level of deformation in
one of the initial homozygous specimens. Although biologically
highly relevant, this specimen was excluded from the shape
analyses to preclude any undue influence of this outlier.
Generalized procrustes analysis (GPA) was used to quantify and
visualize the localized shape differences among the groups as
implemented in the R ‘‘shapes’’ package [37]. The bones were
ordinated in shape-space using principal components analysis.
Each principal component summarizes a unique portion of the
shape variation that is not explained by any of the preceding
components. Typically, the morphospace is centered on the mean
(or consensus) shape configuration of the GPA, so that the each
point in the morphospace can be visualized as deviation from the
mean shape. Principal components also can be used as shape
variables on which statistical tests can be applied.
Subsequent to the detailed shape analyses, a further twenty five
Frem1
bat males (thirteen homozygotes, seven heterozygotes, and
five controls) ranging from postnatal day 28 through to postnatal
day 240 were scanned and 3D rendered models generated using
Drishti V2.0 (http://sf.anu.edu.au/Vizlab/drishti/). Five 37 day
old Zdhhc21
dep/dep mice were also obtained for imaging. In addition,
three embryonic day 18.5 Nfib
-/- mice were analysed. All skulls
were visually inspected and any gross malformations recorded.
Analysis of Frem1 expression
Frem1 transcripts were detected using specific riboprobes to the
39 UTR of the gene as described previously [21]. A rabbit
polyclonal Frem1 antisera was raised against Frem1 CSPG
domain 11 and partial domain 12 (aa 1500–1637) expressed and
purified as a His-tagged recombinant protein [38]. Immunohis-
tochemistry was performed on 10 micrometer frozen sections of P0
mouse heads using antibodies to Frem1 (above) and entactin
(Abcam) detected using Alexa conjugated secondary antibodies
(Molecular Probes). Images were captured on a Leica SP5 confocal
microscope.
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